{"title":"Chimerism kinetics in pediatric hematopoietic stem cell transplantation: from biological basis to advanced monitoring technologies.","authors":"Prasad Iyer, Satyendra Katewa","doi":"10.1080/08880018.2026.2634279","DOIUrl":null,"url":null,"abstract":"<p><p>Monitoring donor-recipient chimerism following hematopoietic stem cell transplantation (HSCT) is essential for assessing engraftment success, early identification of graft failure and relapse, and guiding immunomodulating interventions. Recent advancements in molecular technologies, particularly digital droplet PCR (ddPCR) and next-generation sequencing (NGS), have markedly improved the sensitivity and precision of chimerism detection, allowing the identification of recipient cells at levels below 0.1%. These advancements enable more accurate and dynamic monitoring compared to traditional methods, which are limited in terms of sensitivity and specificity. In pediatric patients, the interpretation of chimerism results is complicated by unique factors, including thymic recovery, exposure to serotherapy agents such as ATG or alemtuzumab, and constraints related to small blood volume. These factors affect the kinetics of donor cell engraftment and the dynamics of mixed chimerism in different hematopoietic lineages. This review presents the current understanding of the biological basis of chimerism, compares traditional and advanced detection methodologies, and details lineage-specific chimerism kinetics in children. It also provides practical guidance for interpreting serial chimerism data to inform timely and preemptive clinical interventions. Owing to the limited pediatric-specific data, adult findings were integrated where appropriate, underscoring the urgent need for pediatric validation, assay harmonization, and standardized implementation protocols to optimize transplant outcomes in children.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-15"},"PeriodicalIF":1.2000,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2026.2634279","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Monitoring donor-recipient chimerism following hematopoietic stem cell transplantation (HSCT) is essential for assessing engraftment success, early identification of graft failure and relapse, and guiding immunomodulating interventions. Recent advancements in molecular technologies, particularly digital droplet PCR (ddPCR) and next-generation sequencing (NGS), have markedly improved the sensitivity and precision of chimerism detection, allowing the identification of recipient cells at levels below 0.1%. These advancements enable more accurate and dynamic monitoring compared to traditional methods, which are limited in terms of sensitivity and specificity. In pediatric patients, the interpretation of chimerism results is complicated by unique factors, including thymic recovery, exposure to serotherapy agents such as ATG or alemtuzumab, and constraints related to small blood volume. These factors affect the kinetics of donor cell engraftment and the dynamics of mixed chimerism in different hematopoietic lineages. This review presents the current understanding of the biological basis of chimerism, compares traditional and advanced detection methodologies, and details lineage-specific chimerism kinetics in children. It also provides practical guidance for interpreting serial chimerism data to inform timely and preemptive clinical interventions. Owing to the limited pediatric-specific data, adult findings were integrated where appropriate, underscoring the urgent need for pediatric validation, assay harmonization, and standardized implementation protocols to optimize transplant outcomes in children.
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.